» Articles » PMID: 35877588

Cardiotoxicity of Chemical Substances: An Emerging Hazard Class

Abstract

(1) Background: Human health risks and hazards from chemical substances are well regulated internationally. However, cardiotoxicity, is not defined as a stand-alone hazard and therefore there are no defined criteria for the classification of substances as cardiotoxic. Identifying and regulating substances that cause cardiovascular adverse effects would undoubtedly strengthen the national health systems. (2) Methods: To overcome the aforementioned gap, a roadmap is proposed for identifying regulatory criteria from animal studies and endorse legislation in order to classify substances as cardiotoxic. The roadmap consists of: (i) the identification of the appropriate animal species and strains; (ii) the identification of the lines of scientific evidence (e.g., histopathological, biochemical and echocardiographic indices etc.) from animal studies with relevance to humans; (iii) the statistical analysis and meta-analysis for each line of scientific evidence after exposure to well-established cardiotoxicants to humans (e.g., anthracyclines) in order to identify threshold values or range of normal and/ or altered values due to exposure; (iv) validation of the above described lines of evidence in animals exposed to other alleged cardiotoxic substances (e.g., anabolic androgen steroids (AAS) and pesticides); (v) establishment of mechanisms of action based on information of either known or alleged cardiotoxicants; and (vi) introduction of novel indices and in silico methods. (3) Results: Preliminary results in rats indicate a clear distinction from normal values to values measured in rats exposed to anthracyclines regarding left ventricle (LV) fractional shortening (FS) and LV ejection fraction (EF). A distinctive pattern is similarly observed for Creatine Kinase-Myocardial Band isoenzyme (CK-MB) and cardiac tissue glutathione (GSH). These findings are encouraging and indicate that there is room for targeted research to this end, and that these specific indices and biochemical markers should be further investigated in order to be developed to regulatory criteria. (4) Conclusions: Further research should be conducted by both the scientific and regulatory community that aims to clearly define the cardiotoxicity hazard caused by chemicals and develop a full set of scientific criteria.

Citing Articles

Synergistic Anticancer Efficacy of Curcumin and Doxorubicin Combination Treatment Inducing S-phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells: An In Vitro Study.

Sarkar E, Khan A, Ahmad R, Misra A, Raza S, Mahdi A Cureus. 2025; 16(12):e75047.

PMID: 39749050 PMC: 11695051. DOI: 10.7759/cureus.75047.


Characterizing PFAS hazards and risks: a human population-based in vitro cardiotoxicity assessment strategy.

Ford L, Lin H, Zhou Y, Wright F, Gombar V, Sedykh A Hum Genomics. 2024; 18(1):92.

PMID: 39218963 PMC: 11368000. DOI: 10.1186/s40246-024-00665-x.


Informing Hazard Identification and Risk Characterization of Environmental Chemicals by Combining Transcriptomic and Functional Data from Human-Induced Pluripotent Stem-Cell-Derived Cardiomyocytes.

Tsai H, Ford L, Burnett S, Dickey A, Wright F, Chiu W Chem Res Toxicol. 2024; 37(8):1428-1444.

PMID: 39046974 PMC: 11691792. DOI: 10.1021/acs.chemrestox.4c00193.


Knowledge and attitudes toward the use of anabolic-androgenic steroids among physical education university students: a cross-sectional study from Palestine.

Hattab S, Saleh B, Qasarweh L, Draidi M, Zyoud S Sci Rep. 2024; 14(1):2146.

PMID: 38273101 PMC: 10810783. DOI: 10.1038/s41598-024-52787-w.


Cardiovascular Toxicity Related to Cancer Treatment.

Xanthopoulos A, Briasoulis A J Cardiovasc Dev Dis. 2023; 10(6).

PMID: 37367424 PMC: 10299303. DOI: 10.3390/jcdd10060259.


References
1.
Mikaelian I, Scicchitano M, Mendes O, Thomas R, LeRoy B . Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs. Toxicol Pathol. 2012; 41(1):18-31. DOI: 10.1177/0192623312448939. View

2.
Bostan H, Rezaee R, Valokala M, Tsarouhas K, Golokhvast K, Tsatsakis A . Cardiotoxicity of nano-particles. Life Sci. 2016; 165:91-99. DOI: 10.1016/j.lfs.2016.09.017. View

3.
Baggish A, Weiner R, Kanayama G, Hudson J, Lu M, Hoffmann U . Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017; 135(21):1991-2002. PMC: 5614517. DOI: 10.1161/CIRCULATIONAHA.116.026945. View

4.
Robert J . Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol. 2006; 23(1):27-37. DOI: 10.1007/s10565-006-0142-9. View

5.
Georgiadis N, Tsarouhas K, Tsitsimpikou C, Vardavas A, Rezaee R, Germanakis I . Pesticides and cardiotoxicity. Where do we stand?. Toxicol Appl Pharmacol. 2018; 353:1-14. DOI: 10.1016/j.taap.2018.06.004. View